PATENT CLAIM ANALYSIS

Application Number: 16191247
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["435", "202000"]

Abstract:
Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.

Claim (Index 17):
The benzylisoquinoline alkaloid active pharmaceutical ingredient of  claim 1 , wherein the benzylisoquinoline alkaloid product comprises morphine, and wherein the benzylisoquinoline alkaloid active pharmaceutical ingredient contains neomorphine.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 98.0
- Lexical Diversity: 1.91071
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15360763', '14211611', '16165940', '16149025', '14614484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7011914011381325
- 35 USC 102 Novelty (BERT): 0.6998291673160338
- Combined Prediction Score: 0.7010551777559226
- Mean Citation Score: 557.033872
- Max Citation Score: 782.9426
- Similarity Product: 700.2424883948802

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test